Broomfield B, Tan C, Qin R, Abberger H, Duckworth B, Alvarado C
J Exp Med. 2025; 222(5).
PMID: 40062995
PMC: 11893171.
DOI: 10.1084/jem.20241148.
Cvijovic I, Swift M, Quake S
Proc Natl Acad Sci U S A. 2025; 122(9):e2406474122.
PMID: 40020190
PMC: 11892634.
DOI: 10.1073/pnas.2406474122.
Gabernet G, Maciuch J, Gygi J, Moore J, Hoch A, Syphurs C
bioRxiv. 2025; .
PMID: 39990442
PMC: 11844572.
DOI: 10.1101/2025.02.12.637926.
Santos-Peral A, Zaucha M, Nikolova E, Yaman E, Puzek B, Winheim E
Cell Rep Med. 2025; 6(2):101946.
PMID: 39938525
PMC: 11866508.
DOI: 10.1016/j.xcrm.2025.101946.
Ramos I
mSphere. 2025; 10(2):e0050224.
PMID: 39853092
PMC: 11852852.
DOI: 10.1128/msphere.00502-24.
Combination adjuvant improves influenza virus immunity by downregulation of immune homeostasis genes in lymphocytes.
Dollinger E, Hernandez-Davies J, Felgner J, Jain A, Hwang M, Strahsburger E
Immunohorizons. 2025; 9(2).
PMID: 39849993
PMC: 11841980.
DOI: 10.1093/immhor/vlae007.
MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity.
Grewe I, Friedrich M, Dieck M, Spohn M, Ly M, Krahling V
Front Immunol. 2025; 15:1500615.
PMID: 39749328
PMC: 11693667.
DOI: 10.3389/fimmu.2024.1500615.
System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans.
Cortese M, Hagan T, Rouphael N, Wu S, Xie X, Kazmin D
Nat Immunol. 2025; 26(1):116-130.
PMID: 39747435
DOI: 10.1038/s41590-024-02036-z.
Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans.
Fiore-Gartland A, Srivastava H, Seese A, Day T, Penn-Nicholson A, Luabeya A
Front Immunol. 2024; 15:1441944.
PMID: 39381003
PMC: 11458388.
DOI: 10.3389/fimmu.2024.1441944.
Systemic dysregulation and molecular insights into poor influenza vaccine response in the aging population.
Kumar S, Zoodsma M, Nguyen N, Pedroso R, Trittel S, Riese P
Sci Adv. 2024; 10(39):eadq7006.
PMID: 39331702
PMC: 11430404.
DOI: 10.1126/sciadv.adq7006.
Transforming vaccinology.
Rappuoli R, Alter G, Pulendran B
Cell. 2024; 187(19):5171-5194.
PMID: 39303685
PMC: 11736809.
DOI: 10.1016/j.cell.2024.07.021.
Putting computational models of immunity to the test - an invited challenge to predict vaccination outcomes.
Shinde P, Willemsen L, Anderson M, Aoki M, Basu S, Burel J
bioRxiv. 2024; .
PMID: 39282381
PMC: 11398469.
DOI: 10.1101/2024.09.04.611290.
Mitochondrial Hyperactivity and Reactive Oxygen Species Drive Innate Immunity to the Yellow Fever Virus-17D Live-Attenuated Vaccine.
Muccilli S, Schwarz B, Jessop F, Shannon J, Bohrnsen E, Shue B
bioRxiv. 2024; .
PMID: 39282299
PMC: 11398391.
DOI: 10.1101/2024.09.04.611167.
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis.
Younis B, Wiggins R, Khalil E, Osman M, Santoro F, Sonnati C
Mol Ther Methods Clin Dev. 2024; 32(3):101310.
PMID: 39253357
PMC: 11381778.
DOI: 10.1016/j.omtm.2024.101310.
An innate immune signature induced by AS01- or AS03-adjuvanted vaccines predicts the antibody response magnitude and quality consistently over time.
Tasdighian S, Bechtold V, Essaghir A, Saeys Y, Burny W
Front Immunol. 2024; 15:1412732.
PMID: 39206189
PMC: 11349632.
DOI: 10.3389/fimmu.2024.1412732.
Host Functional Response to a Prototypic Orally Delivered Self-Replicating Vaccine Platform.
Vilander A, Burak J, Gilfillan D, Dean G, Abdo Z
Vaccines (Basel). 2024; 12(7).
PMID: 39066339
PMC: 11281611.
DOI: 10.3390/vaccines12070701.
Deciphering Immune Responses to Immunization via Transcriptional Analysis: A Narrative Review of the Current Evidence towards Personalized Vaccination Strategies.
Papadatou I, Geropeppa M, Piperi C, Spoulou V, Adamopoulos C, Papavassiliou A
Int J Mol Sci. 2024; 25(13).
PMID: 39000206
PMC: 11240890.
DOI: 10.3390/ijms25137095.
A unified metric of human immune health.
Sparks R, Rachmaninoff N, Lau W, Hirsch D, Bansal N, Martins A
Nat Med. 2024; 30(9):2461-2472.
PMID: 38961223
DOI: 10.1038/s41591-024-03092-6.
Feasibility of Using a Type I IFN-Based Non-Animal Approach to Predict Vaccine Efficacy and Safety Profiles.
Abdel-Haq H
Vaccines (Basel). 2024; 12(6).
PMID: 38932312
PMC: 11209158.
DOI: 10.3390/vaccines12060583.
Immunoglobulin and T cell receptor repertoire changes induced by a prototype vaccine against Chagas disease in naïve rhesus macaques.
Dumonteil E, Tu W, Desale H, Goff K, Marx P, Ortega-Lopez J
J Biomed Sci. 2024; 31(1):58.
PMID: 38824576
PMC: 11143712.
DOI: 10.1186/s12929-024-01050-5.